Aldosterone and vascular damage

[1]  D. Duprez,et al.  Inverse relation between aldosterone and venous capacitance in chronically treated congestive heart failure. , 2000, The American journal of cardiology.

[2]  A. Struthers,et al.  Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. , 2000, Circulation.

[3]  Y. Asano,et al.  Aldosterone activates Na+/H+ exchange in vascular smooth muscle cells by nongenomic and genomic mechanisms. , 1999, Kidney international.

[4]  K. Weber,et al.  Extra-adrenal mineralocorticoids and cardiovascular tissue. , 1999, Journal of molecular and cellular cardiology.

[5]  E. Falkenstein,et al.  Aldosterone, not estradiol, is the physiological agonist for rapid increases in cAMP in vascular smooth muscle cells. , 1999, Circulation.

[6]  F. Veglio,et al.  Impaired baroreflex function and arterial compliance in primary aldosteronism , 1999, Journal of Human Hypertension.

[7]  C. Stier,et al.  Downloaded from http://hyper.ahajournals.org / by guest on February 21, 2013Role of Aldosterone in Renal Vascular Injury in Stroke-Prone Hypertensive Rats , 2022 .

[8]  K. Yee,et al.  Aldosterone blunts the baroreflex response in man. , 1998, Clinical science.

[9]  K. Theisen,et al.  Rapid cardiovascular action of aldosterone in man. , 1998, The Journal of clinical endocrinology and metabolism.

[10]  J. Cohn,et al.  Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. , 1998, European heart journal.

[11]  C. Stier,et al.  Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. , 1998, Hypertension.

[12]  J. Blacher,et al.  Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. , 1997, American journal of hypertension.

[13]  K. Weber,et al.  Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. , 1997, Cardiovascular research.

[14]  A. Struthers,et al.  Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. , 1997, Cardiovascular research.

[15]  M. Safar,et al.  Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[16]  M. Christ,et al.  Nongenomic effects of aldosterone on intracellular calcium in porcine endothelial cells. , 1997, The American journal of physiology.

[17]  I. Miyamori,et al.  Vascular aldosterone in genetically hypertensive rats. , 1997, Hypertension.

[18]  E. Porteri,et al.  Vascular hypertrophy and remodeling in secondary hypertension. , 1996, Hypertension.

[19]  T. Morinelli,et al.  Potentiation of angiotensin II action by corticosteroids in vascular tissue. , 1996, Cardiovascular research.

[20]  I. Miyamori,et al.  Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin. , 1996, The Journal of clinical endocrinology and metabolism.

[21]  A. Struthers.  Two new culprits in cardiovascular disease: QT dispersion and aldosterone. , 1995, Journal of human hypertension.

[22]  U. Ikeda,et al.  Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 beta. , 1995, European journal of pharmacology.

[23]  M. Wehling,et al.  Nongenomic effects of aldosterone on intracellular Ca2+ in vascular smooth muscle cells. , 1995, Circulation research.

[24]  Hiroshi Yamamoto,et al.  Aldosterone biosynthesis and action in vascular cells , 1995, Steroids.

[25]  L. Kornel,et al.  Aldosterone (ALDO) increases transmembrane influx of Na+ in vascular smooth muscle (VSM) cells through increased synthesis of Na+ channels , 1995, Steroids.

[26]  C. Bauters,et al.  Neointimal thickening after balloon denudation is enhanced by aldosterone and inhibited by spironolactone, and aldosterone antagonist. , 1995, Cardiovascular research.

[27]  K. Theisen,et al.  Rapid effects of aldosterone on sodium transport in vascular smooth muscle cells. , 1995, Hypertension.

[28]  I. Miyamori,et al.  3. Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells , 1994, The Journal of biological chemistry.

[29]  W. Wang,et al.  Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. , 1994, Hypertension.

[30]  M. Wehling.  Nongenomic actions of steroid hormones , 1994, Trends in Endocrinology & Metabolism.

[31]  R. Dilley,et al.  Mineralocorticoids, hypertension, and cardiac fibrosis. , 1994, The Journal of clinical investigation.

[32]  A. Salvetti,et al.  Vasodilation to acetylcholine in primary and secondary forms of human hypertension. , 1993, Hypertension.

[33]  L. Kornel.  The role of vascular steroid receptors in the control of vascular contractility and peripheral vascular resistance , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[34]  J. Kaufman,et al.  Influence of systemic arterial blood pressure and nonhemodynamic factors on the brachial artery pulsatility index in mild to moderate essential hypertension. , 1993, The American journal of cardiology.

[35]  D. Schohn,et al.  Dose-related cardiovascular effects of spironolactone. , 1993, The American journal of cardiology.

[36]  E. Baulieu,et al.  Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. , 1992, Circulation research.

[37]  P. Armstrong,et al.  Remodeling and reparation of the cardiovascular system. , 1992, Journal of the American College of Cardiology.

[38]  I. Zucker,et al.  Aldosterone reduces baroreceptor discharge in the dog. , 1992, Hypertension.

[39]  J. Funder,et al.  Vascular type I aldosterone binding sites are physiological mineralocorticoid receptors. , 1989, Endocrinology.

[40]  B. Rossier.  Mechanisms of action of mineralocorticoid hormones. , 1989, Endocrine research.

[41]  T. R. Hansen,et al.  Hypertension, Transmural Pressure, and Vascular Smooth Muscle Response in Rats , 1975, Circulation research.

[42]  J. Laragh,et al.  Essential hypertension: renin and aldosterone, heart attack and stroke. , 1972, The New England journal of medicine.

[43]  H. Langford,et al.  Effect of DCA on development of renoprival hypertension. , 1959, The American journal of physiology.

[44]  P. Redleaf,et al.  Effect of hypertension on arterial wall electrolytes during desoxycorticosterone administration. , 1957, The American journal of physiology.